This phase I study is assessing how safe, tolerable and effective a targeted therapy (VAY736) is alone, and in combination with cancer drug lenalidomide, in people with relapsed or refractory B-cell non-Hodgkin lymphomaA Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL)

Exclusion

• Baseline laboratory results outside of protocol defined ranges
• Patients with primary CNS lymphoma
• History of hypersensitivity to VAY736 or any drugs in similar chemical classes (e.g. monoclonal antibodies)
• Impaired cardiac function or clinically significant cardiac disease
• History of or current interstitial lung disease or pneumonitis grade 2 or higher
• HIV infection
• Active hepatitis C infection and/or hepatitis B infection
• Pregnant or nursing (lactating) women
• Women of child-bearing potential unless they are using highly effective methods of contraception

Other Inclusion/Exclusion criteria may apply